1、Luca Busetto et al.Presented at the 33rd European Congress on Obesity(ECO),May 1215,2026;Istanbul,Trkiye.Scan QR code or visit the website below for:Science Hub linkshttps:/ and achievement of BMI and waist-to-height ratio treatment targets:REDEFINE 1Luca Busetto1,Cynthia Karenina Osorto Contreras2,
2、Mikkel Hovden Christensen2,Deborah Horn3,Carel W.le Roux4,5,Barbara McGowan6,Claire Prener Miller2,W.Timothy Garvey71Department of Medicine,University of Padova,Padova,Italy;2Novo Nordisk A/S,Sborg,Denmark;3Center for Obesity Medicine and Metabolic Performance,University of Texas McGovern Medical Sc
3、hool,Houston,TX,USA;4Diabetes Complications Research Centre,Conway Institute,University College Dublin,Dublin,Ireland;5Diabetes Research Centre,Ulster University,Coleraine,UK;6Guys and St.Thomas NHS Foundation Trust,London,UK;7University of Alabama at Birmingham,Birmingham,AL,USA.This study was fund
4、ed by Novo Nordisk A/S and is registered with ClinicalTrials.gov(NCT05567796).Medical writing support was provided by James Parkinson,PhD,CMPP,of OPEN Health Communications,and funded by Novo Nordisk A/S,in accordance with Good Publication Practice(GPP)guidelines(ismpp.org/gpp-2022).Previously prese
5、nted at the 43rd Annual Meeting of The Obesity Society)held at ObesityWeek,November 47,2025,Atlanta,GA,USA.AD04.03Luca Busetto et al.Presented at the 33rd European Congress on Obesity(ECO),May 1215,2026;Istanbul,Trkiye.2Presenter disclosureLuca Busetto reports the following:Luca Busetto declares rec
6、eiving speaker fees from Pronokal and Rhythm Pharmaceuticals;and received consulting fees from Amgen,Boehringer Ingelheim,Bruno Farmaceutici,Eli-Lilly,Novonordisk,Pfizer,Recordati,Regeneron,and Roche.Luca Busetto et al.Presented at the 33rd European Congress on Obesity(ECO),May 1215,2026;Istanbul,Tr